Bavarian Nordic – Completion of Share Buy-Back Program - May 11, 2026
Bavarian Nordic – Completion of Share Buy-Back Program - May 11, 2026
COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an aggregate amount of approximately DKK 200 million as planned. This represented the second tranche of a total planned share buy-back of up to DKK 500 million in 2026. Combined with the first tranche, shares of a total aggregate amount of approximately DKK 350 million have now been repurchased. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure.
The program was executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.
A total of 1,050,863 shares were purchased under the program. Since the last announcement of transactions on May 4, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic:
Number of shares
Average purchase price, DKK
Transaction value, DKK
Accumulated until May 4, 2026
900,295
190.54
171,542,112
May 4, 2026
10,624
187.64
1,993,447
May 5, 2026
42,816
189.69
8,121,694
May 6, 2026
47,000
188.32
8,851,167
May 7, 2026
45,000
189.49
8,526,870
May 8, 2026
5,128
188.09
964,540
Accumulated under the program
1,050,863
190.32
199,999,830
The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.
Following these transactions, Bavarian Nordic holds a total of 2,748,624 treasury shares, corresponding to 3.47% of the Company’s share capital.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com